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AbstrACt
Introduction Patients with liver cirrhosis are often 
diagnosed late and once complications are present, the 
2- year survival is 50%. Increasing evidence supports 
systemic inflammation and metabolic dysfunction in 
the hepatic stellate cell as key drivers of progression of 
cirrhosis. However, there is no registered medication, that 
targets inflammation and cellular dysfunction in the liver.
Methods and analysis In a randomised double- blind and 
placebo- controlled trial with atorvastatin for liver cirrhosis, 
we aim to investigate clinical endpoints of survival, 
hospitalisations and safety, but also exploratory endpoints 
of genomics and protein functions in the liver.
Ethics and dissemination There is no registered 
medication that actively prevents development of 
complications or systemic inflammation in liver cirrhosis. 
All patients continue regular clinical management during 
the trial period. Atorvastatin has been on the market 
for several years with a safety profile that is acceptable 
even in patients with liver disease. A beneficial effect 
of atorvastatin on clinical outcomes in cirrhosis will 
provide cheap and effective causal treatment for chronic 
liver disease. The trial is registered by the Danish Data 
Protection Agency (P-2019–635) and approved by the 
Danish Medicines Agency (EudraCT 2019-001806-40) and 
the Scientific Ethics Committee of the Capital Region of 
Denmark (H-19030643) before initiation. Reporting of the 
trial will follow the Consolidated Standards of Reporting 
Trials guidelines for reporting of randomised clinical trials.
trial registration number The trial is registered in  
clinicaltrials. gov (NCT04072601) and in  clin ical tria lsre 
gister. eu (EudraCT 2019-001806-40) (Pre- results).
IntroduCtIon
In Denmark, the incidence of liver cirrhosis 
has increased fivefold for men and tripled for 
women over the last 40 years. Approximately 
1600 people are diagnosed with liver cirrhosis 
every year.1 Patients readmitted to hospital 
have higher 90- day mortality than those who 
avoid readmission.2
The high incidence of liver cirrhosis in 
Denmark is caused by a combination of 
genetic susceptibility, a wide use of alcohol 
and a population increasing in age and body 
mass index. Patients with liver cirrhosis are 
often diagnosed late and once complica-
tions are present, the 2- year survival is 50%.3 
Systemic inflammation predisposes to an 
excess risk of infections and mortality.4
Treatment of liver cirrhosis has focused on 
addressing isolated complications and not on 
causal factors driving the development and 
progression of the disease. The scientific liter-
ature is characterised by only few randomised 
trials evaluating new pharmacological treat-
ment principles.5–7 In the past decade, 
increasing evidence supports systemic inflam-
mation and metabolic dysfunction in the 
hepatic stellate cell as key drivers of progres-
sion of cirrhosis.8 9 Only a few studies assess 
combination therapy with potential effects on 
inflammation in the liver, on portal venous 
blood pressure and kidney function, and 
evidence is scarce in this area.10 At present, 
there is no registered medication that targets 
inflammation and cellular dysfunction in the 
liver.
Use of statins (3- hydroxy-3- methylglutaryl–
coenzyme A reductase inhibitors) in cirrhosis 
may reduce the risk of complications and 
mortality.11 12
Several studies have demonstrated the 
beneficial effects of statins in vascular and 
strengths and limitations of this study
 ► The trial is double blind and placebo controlled.
 ► The trial has primary clinical endpoints of mortality 
and hospitalisation.
 ► The trial has secondary endpoints in exploratory 
studies of liver dysfunction and disease progression.
 ► The trial applies novel omics techniques in decom-
pensated liver disease.
 ► The trial design includes 18 months of treatment 
and up to 5 years of follow- up.
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Figure 1 Trial flow.
heart disease.13 14 Statins have antithrombotic effects, 
decrease oxidative stress and inflammation at the vessel 
wall, and improve endothelial dysfunction by increasing 
nitric oxide (NO) production in endothelial cells.15–17 
In cirrhosis, endothelial NO release is impaired in the 
liver microvasculature and is a major contributor to the 
increased hepatic resistance and development of portal 
hypertension.18 19
In rodent models, statins are shown to decrease intrahe-
patic vascular resistance and improve flow- mediated vaso-
dilation of liver vasculature in the cirrhotic liver. These 
effects are mediated by an upregulation of NO produc-
tion at the liver vasculature through an enhancement in 
endothelial NO synthase activity.20 21 Statins seems also to 
inhibit fibrogenesis in cirrhotic rats.22 In recent years, a 
series of pilot studies have assessed the effects of simvas-
tatin on portal hypertension.5 23–25
Lately, a large randomised trial showed an effect 
of simvastatin on mortality, but not on rebleeding in 
patients with cirrhosis and previous variceal bleeding.12 
In a Danish national registry study, use of statins reduced 
the risk of mortality among patients with cirrhosis.26 
Evidence supporting the use of statins in a real- world clin-
ical setting, and data on the effects on inflammation and 
generation of fibrosis in the liver in humans is in high 
demand.
Atorvastatin is a potent and widely used drug with less 
toxicity and a better safety profile than other statins.13 27 
It has demonstrated inhibitory effects on development of 
cirrhosis and hepatocellular carcinoma as well as similar 
beneficial effects on portal hypertension.28 29 Despite these 
promising effects, international experts agree that further 
randomised controlled trials in large series of patients 
with hard clinical endpoints should be performed before 
statins can be recommended for use in clinical practice.30
Mass spectrometry- based proteomics technology is 
constantly improving. In 2016, a robust and scalable 
sample preparation technology for the human plasma 
proteome was developed, and an inflammatory protein 
pattern was defined and quantified dynamically in a 
clinical trial.31 32 Recent advances now allow rapid quan-
tification of a complete proteome in simple organisms 
and near exhaustive proteomes of mammalian cells.33 34 
Bioinformatics analysis is continuously evolving,35 36 and 
have in recent years moved in to the field of translational 
research. Performance of proteomics on human liver cells 
with advanced disease and with systemic inflammation 
will allow us to explore drug efficacy and pharmacody-
namics at the highest level available, protein transcription 
and expression in the hepatic cells.
Genome- wide association studies have identified 
large numbers of single cell nucleotide polymorphisms 
associated to insulin resistance, and other metabolic 
traits related to metabolism and progression of liver 
fibrosis.37 38 From whole genome sequence data, informa-
tion on both rare variants and common single nucleotide 
polymorphisms (SNPs) can be extracted, and a global 
reference system for relevant traits can be defined and 
used in development of risk algorithms. Recently devel-
oped single- cell RNA- sequencing methods and cell- free 
DNA sequencing enables unbiased and high- throughput 
transcriptomic analyses of individual cells and an estimate 
of turnover of individual cell types in the liver.39 40
This trial will investigate whether atorvastatin improves 
survival or delays onset of systemic inflammation and 
decompensation in cirrhosis. Secondarily, the trial will 
assess whether macrophage activation, immune response 
or protein expression in the hepatic stellate cell are 
altered by atorvastatin treatment.
MEthods And AnAlysIs
In a two- centre, randomised, double- blind and placebo- 
controlled clinical trial, participants will be allocated to 
atorvastatin 10–20 mg daily or placebo in a 1:1 ratio. Study 
flow and investigations are stated in figure 1. Initiation of 
the trial is planned for October 2019.
selection of participants
The trial will take place in two university hospitals with 
referral from other hospitals, hospital departments 
and general practice. Patients referred to the outpa-
tient clinics or hospitalised in the Gastro Unit, Medical 
Division, Copenhagen University Hospital Hvidovre 
and Department of Hepatology and Gastroenterology, 
3Kimer N, et al. BMJ Open 2020;10:e035284. doi:10.1136/bmjopen-2019-035284
Open access
Aarhus University Hospital, are eligible for inclusion. On 
average, 225 people are every year diagnosed with liver 
cirrhosis in these two departments which will supply for 
adequate inclusion. Patients will be offered enrolment 
within 3 months of diagnosis.
Patients with liver cirrhosis, diagnosed by liver biopsy, 
ultrasound or CT scan of the liver, and clinical biochem-
istry compatible with cirrhosis are eligible for inclusion. 
Participants must have portal hypertension with a hepatic 
venous pressure gradient measured by liver vein cathe-
terisation >10 mm Hg. In women, documented absence 
of pregnancy and, unless in menopause, commitment to 
use adequate contraception. Participants must be able to 
read and understand project information in Danish and 
give written, informed consent to participation.
Patients are excluded if they are treated with statins 
within the last year; are pregnant or breast feeding; have 
hepatocellular carcinoma; HIV infection and receive 
treatment with protease inhibitors; or Model for end- 
stage liver disease (MELD) score above 23 or Child- Pugh 
score higher than 13.
Patients with liver cirrhosis and a clinically verified 
infection (standard biochemistry, culture) within the 
last 4 weeks; patients with clinical and biochemical signs 
of hepatorenal syndrome defined by current guidelines 
within the last 14 days41; patients with hepatic enceph-
alopathy grade 2 or higher; and patients in whom the 
clinician and investigators may have reason to doubt 
compliance to trial medication will also be excluded.
Dyslipidaemia is not an exclusion criterion. However, 
treatment effects on cholesterol levels will not be moni-
tored during the trial but will be measured by routine lab 
and blinded to investigators and clinical personnel.
Interventions
The intervention group will receive atorvastatin 10 mg 
capsules daily for 78 weeks in addition to standard treat-
ment. Dose will be adjusted to 20 mg after 4 weeks of 
treatment if tolerated by the trial participant.
The control group will receive placebo capsules, iden-
tical in shape, size and colour to atorvastatin 10 mg, one 
capsule daily for 78 weeks in addition to standard treat-
ment. Dose will be adjusted to two capsules daily after 4 
weeks of treatment, if the trial participant tolerates it.
Discontinuation of trial drug will be performed in 
case of: the participant withdraws informed consent; 
the participant reach a primary endpoint (death or liver 
transplantation); the participant experiences serious 
adverse events that cause a risk to the participant’s life or 
viability; the participant develops toxicity, intolerance or 
allergy associated with intervention medication; the trial 
participant is admitted to hospital for other morbidity 
that is incompatible with further treatment with atorvas-
tatin; or blinding is revealed.
Physicians with training in Good Clinical Practice (GCP) 
will perform specific tasks of information, screening and 
obtaining informed consent. Staff physicians and project 
nurses will secure adequate recruitment. In case of slow 
recruitment, a third investigating site will be opened 
(Copenhagen University Hospital Rigshospitalet). Partic-
ipants give informed consent to participation and sepa-
rate informed consent to storage of biological material, 
as required by Danish Legislation.
Assignment of interventions
Randomisation is computer generated in block rando-
misation of every six patients. The randomisation list is 
generated by The Regional Pharmacy, University Hospital 
Herlev, who packages and blinds medication. Participants 
are allocated to treatment by a unique study drug ID 
(consecutive numbers). Each number refers to a study 
drug (active or placebo). The randomisation and identifi-
cation lists are stored at The Regional Pharmacy, Univer-
sity Hospital Herlev. To achieve complete blindness of 
trial participants and personnel, a comparator similar in 
size, shape and colour is used.
Atorvastatin tablets 10 mg can be repackaged into 
capsules with flavourless and colourless filler, and a 
placebo capsule with only filler that has no medicinal or 
biological effects is manufactured.
The sponsor, principal investigator, subinvestigators 
and all personnel handling patients in daily clinic will 
be blinded to interventions. One laboratory pharmacist 
responsible for packing and blinding of medication will 
be unblinded. This person is physically located at The 
Regional Pharmacy, University Hospital Herlev and is not 
involved in trial specific routines. A series of envelopes 
produced by the above mentioned unblinded pharmacist 
with each identification number will allow for unblinding 
of each individual participant if necessary.
Study drugs will be distributed to participants at base-
line, at 1 and 3 months and thereafter every 3 months. 
Participants are asked to bring back remaining tablets 
and containers for registration every 3 months. Returned 
number of tablets are registered. Accounting of study 
medication is performed after 6 and 18 months for evalu-
ation of adherence to medication.
sample size
The following is based on data from a previous Danish 
cohort of patients with liver cirrhosis and decompensa-
tion at the time of diagnosis and recent studies of simvas-
tatin in cirrhosis.3 12
Prior data indicate a median survival time between 13 
and 48 months, depending on the progression of liver 
disease and type of decompensation.3 A former trial in 
a population of patients with decompensated cirrhosis 
reported a relative risk reduction to 0.39 in the statin 
group.12
A conservative sample size estimate is therefore based 
on the following trial conditions: (1) one control per 
experimental subject, (2) an inclusion period of 24 
months, (3) an additional follow- up after end of inclusion 
of 24 months.
Prior data may indicate that the median survival time 
on the control treatment is 35 months. If the true HR 
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Figure 2 Graphical abstract.
Table 1 Investigational programme
Visit Time Investigations
Visit 0 Screening Screening for eligibility, exclusion and inclusion criteria. Informed consent if not 
already given.
Visit 1 Day 1: enrolment Enrolment, transjugular liver biopsy, haemodynamic investigations, DEXA scan.
Visit 1 Day 1: randomisation Randomisation, sampling for biobank, biochemistry, Short Physical Performance 
Battery, life space assessment, medication.
Visit 2 Day 20–35 (1 month) Dose adjustment, safety, biochemistry for safety including creatine kinase.
Visit 3 Day 85–100 (3 months) Dose adjustment, safety, biochemistry and sampling for biobank.
Visit 4 Day 175–190 (6 months) Dose adjustment, safety, biochemistry, sampling for biobank, transjugular liver 
biopsy, haemodynamic investigations, DEXA scan, Short Physical Performance 
Battery, life space assessment.
Visit 5 Day 265–280 (9 months) Dose adjustment, safety, biochemistry.
Visit 6 Day 355–370 (12 months) Dose adjustment, safety, biochemistry and sampling for biobank.
Visit 7 Day 450–465 (15 months) Dose adjustment, safety, biochemistry.
Visit 8 Day 535–550 (18 months) Dose adjustment, safety, biochemistry, sampling for biobank, end of study 
medication, Short Physical Performance Battery, life space assessment.
Follow- up Day 540–1825 Data registration on mortality and hospitalisations from clinical registries.
of control subjects relative to experimental subjects is 
0.52, we will need to study 70 experimental subjects and 
70 control subjects to reject the null hypothesis that the 
experimental and control survival curves are equal with a 
probability of 0.85. The type I error probability associated 
with the test of this null hypothesis is 0.05.
With an expected dropout rate of 15%, we plan to enrol 
162 participants.
outcomes
The clinical trial will apply a three- dimensional approach 
in investigating the mechanisms of atorvastatin in 
cirrhosis: (1) the patient level, (2) the human physiology 
level and (3) the cellular level (see figure 2, graphical 
abstract).
The primary endpoints are: composite endpoint of 
numbers of death or liver transplantation after 1.5 years, 
and hospitalisation with liver related complications after 
1.5 years. Secondary endpoints on the patient level are: 
(1) survival (2) adverse events, (2) decompensation of 
liver cirrhosis and time to decompensation, (3) clinical 
scores of Child and MELD, (4) frailty evaluated by the 
Life Space Assessment Questionnaire and the Short Phys-
ical Performance Battery.42 43
Further, on the human physiology level, exploratory 
endpoints are: impact on inflammation and macro-
phage activation measured by immunohistochemistry 
of the stellate cell in combination with PCR analysis for 
specific markers of inflammation in blood, macrophage 
activation and haemodynamic investigations of portal 
hypertension and effect on hepatic venous pressure 
gradient.
Exploratory endpoints on the cellular level: (1) Cellular 
activation. Gene activation by transcriptomics of mRNA 
on the hepatic stellate cell. Gene analyses and single cell 
transcriptomics allow for investigation of gene activity 
and inclusion of genetic traits in risk prediction models 
for disease progression. (2) Protein activity in the hepatic 
stellate cell. By high- sensitivity Mass spectrometry- based 
proteomics, we will perform analysis of hepatic stellate 
cells and Kupffer cells under atorvastatin influence. (3) 
Characterisation of the human microbiome with shotgun 
metagenomic sequencing of all DNA, at a depth of 
30 million paired end reads (9 GB, 2×150 bp), and asso-
ciation to disease progression will be conducted. Since 
microbiome analysis and omics technologies are rapidly 
evolving, a detailed plan for analysis will be conducted 
after baseline sampling, to ensure low cost and resource 
efficiency.
The investigational programme is stated in table 1. For 
the exploratory outcomes of human physiology and cell 
pathology, a biobank containing blood, liver tissue and 
stool is created.
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safety
Initial dose of study drug is 10 mg which can be increased 
to 20 mg after 2–4 weeks if the participant does not 
develop side effects. Creatine kinase and standard 
biochemistry including liver enzymes are measured for 
safety reasons after 2 weeks, to rule out myositis and liver 
damage. Side effects and events are consecutively regis-
tered throughout the trial.
data analysis and data management
The primary outcomes will be analysed as a time to event 
variable, and groups are compared with the stratified log- 
rank test and HR by using the Cox model adjusting by the 
clinical scores MELD and Child. Survival will be analysed 
by the Kaplan- Meier method.
For continuous outcome variables, a mixed model anal-
ysis or Generalized Estimating Equations will be applied. 
Adjustment for baseline differences will be taken into 
account by a longitudinal analysis of covariance. Contin-
uous variables measured repeatedly over time is analysed 
through mixed models for repeated measurements.
Omics technologies are developing rapidly and statis-
tical methods for handling big data evenly. A complete 
data analysis plan will be performed before initiation of 
the exploratory analyses.
Statistical analyses will be performed as per protocol 
and as intention to treat analyses. Missing data will not be 
replaced but left blank in statistical analysis. For intention 
to treat analyses on repeated measures, the last available 
value will be carried forward to last value.
Data are stored in a Redcap database. The trial is 
monitored by the GCP Unit, University of Copenhagen, 
and site- specific data managers. The trial follows the 
guidelines of International Conference of Harmoniza-
tion - Good Clinical Practice (ICH- GCP), and the Trial 
Master File will serve as source for Standard Operating 
Procedures, data agreements, contracts, study guide and 
communications between sites. Definition and handling 
of adverse events follow the ICH- GCP guidelines.
EthICs And dIssEMInAtIon
Patient and public involvement
Patients or the public were not involved in trial design. The 
authors adhere to the Ethical guidelines of the Declaration 
of Helsinki, aiming to protect the life, health, dignity, integ-
rity, right to self- determination, privacy and confidentiality 
of personal information of research subjects.
The present clinical trial will assess possible effects of 
adding atorvastatin to standard treatment in preventing 
disease progression and complications to liver cirrhosis. 
Hence, trial participants who choose to participate in 
the trial will receive standard of care according to rele-
vant medical guidelines for treatment and prevention of 
complications to liver cirrhosis.41
Half of participants will receive placebo medicine. At 
present, there is no registered medication that prevents 
systemic inflammation or actively prevents development or 
onset of complications to liver cirrhosis, and it is yet to be 
proven if statins have effects on these parameters. Partic-
ipants are not withheld active medication. All patients 
continue their regular prescribed medication during the 
trial period.
Former clinical and basic science suggest that statin treat-
ment may ameliorate the systemic and local inflammation 
cascade involved in the progression of liver cirrhosis and 
complications hereto.21 30 44 Addition of atorvastatin to stan-
dard treatment may improve survival and may decrease 
the risk of developing complications to liver cirrhosis, such 
as delaying onset of ascites, variceal bleeding or delaying 
development of sarcopenia and hepatic encephalopathy 
in any degree. Also, the clinical trial will provide a better 
understanding of disease progression on a cellular level in 
stellate cells and Kupffer cells in the liver, as well as insight 
into which mechanisms drives the inflammatory response 
involved in progression from fibrosis to cirrhosis in the 
liver. However, actual clinical and patient- relevant benefits 
of atorvastatin in cirrhosis are still uncertain.
Participants in the trial may experience extra discom-
fort in relation to having a second liver biopsy done after 
6 months of treatment. These nuisances may be pain in 
relation to procedures and a minimal (<0.9%) but extra 
risk of bleeding after procedures.45 Participants in the 
trial will be subject to monthly hospital visits for 3 months 
and then 3 monthly visits until end of trial. However, the 
regular follow- up as recommended for liver patients varies 
between every 14 days to yearly visits to hospital, and the 
disadvantage of participating in the clinical trial with regard 
to hospital visits is therefore difficult to assess. Combination 
of study visits and regular outpatient visits are pursued to 
minimise the time spent in hospital for participants.
The tolerability of statins has been evaluated in 
numerous trials in different patient populations.12 14 46 
Possible side effects are rare or very rare, and include 
abdominal pain, mild hepatitis, pancreatitis, anaemia, 
myopathies or peripheral neuropathies or allergic reac-
tions. Meta- analyses have found that statins are equally 
safe as control treatment regarding adverse and serious 
adverse events, and that rates of discontinuation and the 
most frequent side effect myopathy were equal between 
simvastatin and placebo in clinical trials.14 46 Safety of 
statins in chronic liver disease has been assessed in only 
a few clinical trials, but reviews of observational studies 
report high safety and low risk of adverse events.10 47 48
Recruitment of participants will follow Danish Legisla-
tion and data concerning trial participants will be protected 
under the Data Protection Regulation and the Act on 
Health (Sundhedsloven). Advertisement or recruitment 
will not be performed outside public hospitals.
dissemination of results
Results on all outcomes will be sought published in inter-
national journals with peer review. A preliminary plan 
for dissemination prioritises data in to the following 
groups: primary endpoints including safety, inflam-
mation and links to macrophage activation and gut 
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microbiome; exploratory manuscripts on metagenomics 
and proteomics.
Listing of authors will follow the International 
Committee of Medical Journal Editors’ recommenda-
tions for authorship.49
Perspectives
Atorvastatin has been on the market for several years with 
a safety profile that is acceptable even in patients with 
liver disease. Retrospective and register studies have eval-
uated the safety and risks of statins in cirrhosis.10 30 50 A 
beneficial effect of atorvastatin on clinical outcomes in 
preventing disease progression and decompensation of 
cirrhosis will provide cheap and effective causal treat-
ment directed at cirrhosis and fibrogenesis and not just 
symptom relief in decompensated liver disease.
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